Triallo Logo
  • Home
  • Search
  • Contact

Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty

Triallo

Triallo is a platform that connects patients with life-changing clinical trials. Find hope, access innovative treatments, and contribute to medical breakthroughs.

© 2026 Triallo. All rights reserved.

Privacy PolicyTerms of Service
2261-2280 of 3,900 trials

Bipolar Mania: Lumateperone Study

We are evaluating the safety and effectiveness of lumateperone for treating manic episodes in patients with bipolar I disorder. This study compares the medication to a placebo to see how well it works.

Bipolar Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Allopurinol for Brain Protection in Newborns with Heart Disease

We are studying whether allopurinol can help reduce brain injury in newborns with critical congenital heart disease during and after cardiac surgery. This trial will also assess its effects on brain and heart function, as well as overall development.

Brain Injury in Neonates with Congenital Heart Disease>2 yearsConfirmation phase (III)Standard MedicinesCardiologyNeurologyPediatrics

Crohn's Disease: RO7790121 Treatment Study

We are evaluating a new treatment for people with moderately to severely active Crohn's disease to see if it helps improve symptoms and quality of life compared to a placebo.

Moderately to Severely Active Crohn's DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Advanced Solid Tumors: PM534 Treatment Study

We are testing a new drug called PM534 in patients with advanced solid tumors. The goal is to learn more about its safety and how it may work in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Frozen Shoulder Treatment: Corticosteroid Injection with Nerve Block

We are studying whether a corticosteroid injection combined with a nerve block provides better pain relief and shoulder function than an injection with a placebo. This trial aims to help improve treatment strategies for patients with Frozen Shoulder.

Frozen ShoulderAdhesive Capsulitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

HPV Vaccination After Cervical Lesion Treatment

We are studying whether a secondary HPV vaccination helps women over 45 who have been treated for high-grade cervical lesions achieve HPV-negative status and reduce the risk of recurrence or cancer.

High-Grade Cervical Intraepithelial Lesions>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Metastatic Non-Small Cell Lung Cancer: Ivonescimab vs Pembrolizumab

We are studying whether ivonescimab combined with chemotherapy helps patients with metastatic non-small cell lung cancer live longer and manage their disease better than pembrolizumab with chemotherapy.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Cryptogenic Stroke: STOP Trial on Blood Thinners

We are studying whether stopping blood thinners is as safe as continuing them for young people after a stroke with no known cause. This research may help understand the best approach to prevent future heart problems.

Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

TDP-43 Proteinopathies: New Imaging Agent Study

We are testing a new PET imaging agent to see if it can effectively identify TDP-43 inclusions in the brains of patients suspected of having related conditions. This study compares results with healthy individuals to assess its potential.

Alzheimer's DiseaseFamilial and Sporadic Amyotrophic Lateral SclerosisFamilial and Sporadic Frontotemporal DementiaSafety phase (I)NeurologyPsychiatry

MEN1703 for Aggressive B-cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of MEN1703 alone and with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. This research aims to find better treatment options for this challenging cancer.

Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Small Cell Lung Cancer: BI 764532 Dosing Study

We are testing different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. This study aims to find the most effective dose for these specific cancers.

Small Cell Lung Carcinoma>2 yearsSafety phase (I)Oncology

Outpatient Surgery: Dexmedetomidine Study

We are examining how dexmedetomidine affects blood flow and heart function in patients undergoing scheduled outpatient surgery. This research may help improve anesthesia practices.

Induction of Anesthesia>2 yearsConfirmation phase (III)Internal MedicineOtolaryngology

Vaginal Progesterone for Fertility: Standard vs. New Formulation

We are comparing two formulations of vaginal progesterone to see which one better supports pregnancy in women undergoing fertility treatments. This study aims to improve pregnancy rates and assess safety for participants.

Infertility>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Healthy Volunteers Needed for New Autotaxin-Inhibitor Study

We are testing a new drug, MJK2134025, to see how it affects healthy individuals. This study will help us understand its safety and how different doses work.

StrokeSafety phase (I)AllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNeurologyOncologyOrthopedics and TraumatologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Oxygen Management During Anesthesia: The LOWOX Trial

We are studying whether a tailored approach to oxygen levels during anesthesia improves recovery and oxygen levels after surgery compared to standard fixed oxygen use. This trial involves patients undergoing various surgical procedures.

Surgery under General Anesthesia3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Head and Neck Cancer: New Drug Combinations

We are studying a new combination of drugs for patients with recurrent or metastatic head and neck cancer. The goal is to see if this combination works better than the current treatment options.

Recurrent Head and Neck Squamous Cell CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

HER2-Positive Gastric Cancer: Trastuzumab Deruxtecan Study

We are testing a new treatment combining Trastuzumab Deruxtecan with chemotherapy for patients with advanced HER2-positive gastric or GEJ cancer. The goal is to see if this combination works better than the current standard treatment.

Metastatic Gastric Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology
1...112113114115116...195